Table 1 Patient characteristics and outcome
From: Mortality in patients treated with intravitreal bevacizumab for age-related macular degeneration
Treated with bevacizumab (N = 5385) N (%) | Not treated with bevacizumab (N = 10,756) N (%) | P-value | |
|---|---|---|---|
Age Start [mean ± SD] | 81.17 ± 8.91 | 80.88 ± 8.91 | .051 |
Male | 2460 (45.7) | 4916 (45.7) | .979 |
Married | 2180 (40.5) | 4637 (43.1) | < .001 |
Socioeconomic statusa | <.001 | ||
High | 1213 (22.6) | 2910 (27.1) | |
Medium | 2510 (46.7) | 4620 (43.1) | |
Low | 1652 (30.7) | 3190 (29.8) | |
Cataract | 2353 (43.7) | 3585 (35.9) | < .001 |
Smoking | 1008 (18.7) | 1555 (14.5) | < .001 |
Alcohol | 27 (.05) | 64 (.06) | .524 |
Hypertension | 4142 (76.9) | 7666 (71.3) | < .001 |
Diabetes mellitus | 1821 (33.8) | 3019 (28.1) | < .001 |
Obesity | 1413 (26.2) | 2581 (24.0) | < .001 |
Congestive heart failure | 538 (10.0) | 893 (8.3) | < .001 |
Liver cancer | 4 (.01) | 6 (.01) | .913 |
Ischemic heart disease | 2030 (37.7) | 3434 (31.9) | < .001 |
Cerebrovascular accident | 857 (15.9) | 1508 (14.0) | < .001 |
Mortality | 1063 (19.7) | 1298 (12.1) | < .001 |